Cargando…

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma

Stable nucleic acid lipid vesicles (SNALPs) encapsulating miR-34a to treat multiple myeloma (MM) were developed. Wild type or completely 2′-O-methylated (OMet) MiR-34a was used in this study. Moreover, SNALPs were conjugated with transferrin (Tf) in order to target MM cells overexpressing transferri...

Descripción completa

Detalles Bibliográficos
Autores principales: Scognamiglio, Immacolata, Di Martino, Maria Teresa, Campani, Virginia, Virgilio, Antonella, Galeone, Aldo, Gullà, Annamaria, Gallo Cantafio, Maria Eugenia, Misso, Gabriella, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, Caraglia, Michele, De Rosa, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943297/
https://www.ncbi.nlm.nih.gov/pubmed/24683542
http://dx.doi.org/10.1155/2014/217365
_version_ 1782479210582900736
author Scognamiglio, Immacolata
Di Martino, Maria Teresa
Campani, Virginia
Virgilio, Antonella
Galeone, Aldo
Gullà, Annamaria
Gallo Cantafio, Maria Eugenia
Misso, Gabriella
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
Caraglia, Michele
De Rosa, Giuseppe
author_facet Scognamiglio, Immacolata
Di Martino, Maria Teresa
Campani, Virginia
Virgilio, Antonella
Galeone, Aldo
Gullà, Annamaria
Gallo Cantafio, Maria Eugenia
Misso, Gabriella
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
Caraglia, Michele
De Rosa, Giuseppe
author_sort Scognamiglio, Immacolata
collection PubMed
description Stable nucleic acid lipid vesicles (SNALPs) encapsulating miR-34a to treat multiple myeloma (MM) were developed. Wild type or completely 2′-O-methylated (OMet) MiR-34a was used in this study. Moreover, SNALPs were conjugated with transferrin (Tf) in order to target MM cells overexpressing transferrin receptors (TfRs). The type of miR-34a chemical backbone did not significantly affect the characteristics of SNALPs in terms of mean size, polydispersity index, and zeta potential, while the encapsulation of an OMet miR-34a resulted in a significant increase of miRNA encapsulation into the SNALPs. On the other hand, the chemical conjugation of SNALPs with Tf resulted in a significant decrease of the zeta potential, while size characteristics and miR-34a encapsulation into SNALPs were not significantly affected. In an experimental model of MM, all the animals treated with SNALPs encapsulating miR-34a showed a significant inhibition of the tumor growth. However, the use of SNALPs conjugated with Tf and encapsulating OMet miR-34a resulted in the highest increase of mice survival. These results may represent the proof of concept for the use of SNALPs encapsulating miR-34a for the treatment of MM.
format Online
Article
Text
id pubmed-3943297
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39432972014-03-30 Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma Scognamiglio, Immacolata Di Martino, Maria Teresa Campani, Virginia Virgilio, Antonella Galeone, Aldo Gullà, Annamaria Gallo Cantafio, Maria Eugenia Misso, Gabriella Tagliaferri, Pierosandro Tassone, Pierfrancesco Caraglia, Michele De Rosa, Giuseppe Biomed Res Int Research Article Stable nucleic acid lipid vesicles (SNALPs) encapsulating miR-34a to treat multiple myeloma (MM) were developed. Wild type or completely 2′-O-methylated (OMet) MiR-34a was used in this study. Moreover, SNALPs were conjugated with transferrin (Tf) in order to target MM cells overexpressing transferrin receptors (TfRs). The type of miR-34a chemical backbone did not significantly affect the characteristics of SNALPs in terms of mean size, polydispersity index, and zeta potential, while the encapsulation of an OMet miR-34a resulted in a significant increase of miRNA encapsulation into the SNALPs. On the other hand, the chemical conjugation of SNALPs with Tf resulted in a significant decrease of the zeta potential, while size characteristics and miR-34a encapsulation into SNALPs were not significantly affected. In an experimental model of MM, all the animals treated with SNALPs encapsulating miR-34a showed a significant inhibition of the tumor growth. However, the use of SNALPs conjugated with Tf and encapsulating OMet miR-34a resulted in the highest increase of mice survival. These results may represent the proof of concept for the use of SNALPs encapsulating miR-34a for the treatment of MM. Hindawi Publishing Corporation 2014 2014-02-13 /pmc/articles/PMC3943297/ /pubmed/24683542 http://dx.doi.org/10.1155/2014/217365 Text en Copyright © 2014 Immacolata Scognamiglio et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Scognamiglio, Immacolata
Di Martino, Maria Teresa
Campani, Virginia
Virgilio, Antonella
Galeone, Aldo
Gullà, Annamaria
Gallo Cantafio, Maria Eugenia
Misso, Gabriella
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
Caraglia, Michele
De Rosa, Giuseppe
Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title_full Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title_fullStr Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title_full_unstemmed Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title_short Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
title_sort transferrin-conjugated snalps encapsulating 2′-o-methylated mir-34a for the treatment of multiple myeloma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943297/
https://www.ncbi.nlm.nih.gov/pubmed/24683542
http://dx.doi.org/10.1155/2014/217365
work_keys_str_mv AT scognamiglioimmacolata transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT dimartinomariateresa transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT campanivirginia transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT virgilioantonella transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT galeonealdo transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT gullaannamaria transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT gallocantafiomariaeugenia transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT missogabriella transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT tagliaferripierosandro transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT tassonepierfrancesco transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT caragliamichele transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma
AT derosagiuseppe transferrinconjugatedsnalpsencapsulating2omethylatedmir34aforthetreatmentofmultiplemyeloma